The authors began with a CDK9-preferring scaffold, HS-36, and pursued structure-guided modifications focused on the C-8 side chain and the N-1 substituent. Their medicinal chemistry approach aimed to alter kinase selectivity rather than simply increase potency. This produced a series of chromeno[8,7-d]oxazole derivatives. One compound from that series, named AT-11, emerged with an altered inhibitory profile favoring CDK16/Cyclin Y (CDK16/CycY) over CDK9, as reported in the abstract. The source did not provide full synthetic details or the complete structure-activity table in the abstract text, so those experimental specifics are not available here.
AT-11 inhibited CDK16/CycY with an IC50 value of 125.2 nM in the reported kinase assay. A single-concentration comparison using the same assay conditions indicated a relative shift in the CDK16/CDK9 inhibitory profile compared with the parent HS-36. The authors also tested aqueous solubility. AT-11 showed a measured solubility of 617 μg/mL in PBS at pH 7.4. That level of solubility is explicitly noted in the abstract and is presented as an advantage for the scaffold. The abstract did not include a full kinase selectivity panel, nor did it report assay formats (e.g., ATP concentration or recombinant constructs) in detail; those methodological items were not present in the source text.
In H460 non–small cell lung cancer (NSCLC) cells, AT-11 reduced cell proliferation and colony formation. The compound produced S-phase accumulation in the cell-cycle profile and increased apoptosis. AT-11 also reduced cell migration in H460 assays. When profiled across an expanded panel of tumor and comparator cell lines, AT-11 displayed differential antiproliferative activity: the authors reported low-micromolar GI50 values in H460, A549, and MV-4-11 cells. The abstract does not list GI50 values numerically beyond this description, and it does not supply full panel results or replicate numbers.
Western blot analysis performed in H460 cells after AT-11 treatment revealed two key biomarker changes: reduced relative phosphorylation of p53 at Ser315 and increased total p53 levels. Those observations link AT-11 exposure to modulation of a p53 phosphorylation site that can influence protein stability. The abstract does not specify treatment concentrations, exposure durations, or whether the p53 response is causal for the antiproliferative effects; such protocol details were not reported in the abstract text.
The investigators administered AT-11 intravenously at 20 mg/kg in an H460 xenograft model. Under the tested conditions, a single dosing regimen produced 48.2% tumor growth inhibition. The authors noted that this antitumor activity occurred without marked body-weight loss and without apparent histopathological abnormalities in the tissues examined. The abstract provides these top-line efficacy and tolerability findings but does not include pharmacokinetic parameters, dosing schedule frequency, number of animals per group, or a full histopathology readout; those experimental details are not present in the source abstract.
The abstract positions AT-11 as an early-stage lead compound for CDK16-directed inhibitor development and expands structure-activity knowledge for the chromeno[8,7-d]oxazole scaffold. It reports kinase potency, aqueous solubility, in vitro antiproliferative effects, a set of biomarker changes in H460 cells, and a single in vivo efficacy datum. The source did not report comprehensive kinase selectivity data, full synthetic routes, detailed in vitro assay conditions, pharmacokinetic or metabolic profiling, chronic toxicity studies, or long-term efficacy endpoints in vivo. Those items remain open preclinical questions that would need to be addressed before translation toward clinical testing.
Limitations in the abstract are concrete: selectivity and broader safety data are not shown, and mechanistic causation between CDK16 inhibition and the observed cellular effects is not fully established within the reported text. Future work should define the kinase selectivity matrix, characterize exposure–response relationships with pharmacokinetics, and expand tolerability testing beyond the limited histopathological observations that were reported.